PERSPECTA

News from every angle

← Back to headlines

PharmAla Biotech Secures $100 Million US Licensing Deal for MDMA Therapy

PharmAla Biotech has signed a term sheet for a significant $100 million U.S. licensing deal. The agreement pertains to its ALA-002 MDMA therapy, marking a major development for the company.

20 May, 15:12 — 20 May, 15:12
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual100d ago

PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)

Read full article →

Related Stories

College Dropout Turns Full-Time Pokémon Card Reseller With $7.8M in Sales

36m ago

Fed Chair Warsh Warns of Potential Rate Hikes Amid Stubborn Inflation

1h ago

Temasek Backs Singapore Airlines’ Strategic Investment in Air India

2h ago

Meta Agrees to $18 Billion Settlement Over Teen Safety Lawsuit

2h ago